Gossamer Bio reports Q3 EPS (14c), consensus (15c)

Reports Q3 revenue $9.48M, consensus $7.7M. “Looking forward, we expect 2025 to be an exceptionally important year for Gossamer, as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study. Proper clinical trial execution right now, including enrolling the targeted PAH patients, not only greatly increases the probability of a successful trial, but it also lays the groundwork for what we see as a potential blockbuster pulmonary hypertension franchise. To that end, as we come into the home stretch for 2024, our team remains hard at work, diligently focused on completing PROSERA Study enrollment and designing the registrational Phase 3 PH-ILD clinical trial,” said Faheem Hasnain, Co-Founder, CEO, and Chairman of Gossamer Bio (GOSS).